Dr. Michael Castro and colleagues have joined with the Musella Foundation to raise funds for a proof of concept trial aimed at establishing immunotherapy for the treatment of glioblastoma.
Inducing permanent antitumor immunity is the holy grail of modern oncology...
Investigators recently identified that as many as 80% of GBM patients lack the antigen presenting machinery (APM) coded by MHC1 genes...
Preliminary data from Sweden suggest that GBM patients taking the CMV antibiotic, valganciclovir (Valcyte®) survive longer...
While the idea that blocking CMV would make immunotherapy feasible for GBM patients is deceptively simple...
Dr. Castro proposes a "proof of concept" trial to grow GBM in cell culture and assess whether an absent APM can be coaxed to reappear by treating the cells with Valcyte...
A successful study would serve as a foundation for using PD-1/L1 checkpoint immunotherapy in conjunction with Valcyte...
The study is being led by Dr. Michael P. Castro, a proponent of molecular diagnosis to overcome mechanisms of resistance...
Please donate by using the form on the right. You can also send a check made out to "Musella Foundation" with "APM Rescue Study" in the memo and mail to: 1100 Peninsula Blvd, Hewlett, NY 11557. Call us at 888-295-4740 if you have any problems or questions! Encourage family and friends to donate! Donations are tax deductible to the full extent of the law.
|
If you do donate, please consider checking to see if your employer has a corporate match policy .